This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Endocrine Diseases  • Endocrine Diseases, Other  • Endocrine Surgery  • Prognosis/ Outcomes  • Alert me on articles by topic

Andrew Saxe, MD
Detroit, Mich

Arch Surg. 1999;134:185.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Harrison et al have built on Brennan's long-standing interest in adrenocortical carcinoma, using the Memorial Sloan-Kettering Cancer Center's extensive experience and detailed database to compile a unique report. This series correlates histologic features of resected tumors with clinical outcome, but only in patients undergoing curative surgery. As they properly point out, other investigators have made the same correlation, but not in reports restricted to patients treated with curative surgery. Series "contaminated" by patients undergoing palliative surgery who received adjuvant therapy may obscure more subtle findings that should more properly influence the use of adjuvant therapy. Some may argue that the issue is moot without effective adjuvant agents. Although mitotane has been almost uniformly disappointing, there is hope that taxanes may be effective.

In addition to recording their statistically significant predictors of prognosis, the authors provide other information of interest to me but not emphasized in the article. . . . [Full Text of this Article]

RELATED ARTICLE

Pathologic Features of Prognostic Significance for Adrenocortical Carcinoma After Curative Resection
Lawrence E. Harrison, Paul B. Gaudin, and Murray F. Brennan
Arch Surg. 1999;134(2):181-185.
ABSTRACT | FULL TEXT